BioLineRx Ltd.
BioLineRx Ltd. is an Israel-based biopharmaceutical company focused on developing and commercializing therapeutics in oncology and hematology. Its business centers on clinical-stage drug development, licensed and partnered programs, and the commercialization of motixafortide for stem-cell mobilization in the U.S. and selected ex-U.S. markets through collaborators.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenueApproved and marketed drug products for hematology indications.
Drug candidates in clinical development for cancers such as glioblastoma and pancreatic cancer.
Partnering arrangements that can generate milestones, royalties, and other non-product income.
Internal and partnered development activities supporting pipeline advancement.
Customers
BioLineRx’s direct customers are specialized healthcare providers and treatment centers that use approved hematology products, while its commercialization partner network extends reach across regions. For its pipeline programs, the economic buyers are licensing partners, academic medical centers, and collaborators that fund, study, or commercialize oncology assets. Patient demand is driven by oncology and stem-cell mobilization treatment protocols rather than broad primary-care use.
They buy or prescribe APHEXDA for stem-cell mobilization in multiple myeloma patients.
They enroll patients into GLIX1 and motixafortide oncology studies and support development.
They distribute or commercialize the company's approved product in selected geographies.
They participate in sponsored and investigator-led clinical development programs.
They generate milestone and royalty streams tied to partnered assets and territories.
Strategy
BioLineRx’s strategy is to advance a small number of differentiated oncology assets through clinical development while monetizing approved or partnered products where possible. The company also uses licensing, collaboration, and regional commercialization partners to extend reach and reduce the operational burden of global launches. Building GLIX1 and expanding motixafortide into additional oncology settings are central to long-duration pipeline value creation.
A first-in-class program can create pipeline differentiation if clinical data support efficacy and safety.
Expansion into larger oncology settings can extend the asset beyond stem-cell mobilization.
Partner-led distribution can widen market access while limiting direct commercial infrastructure needs.
Milestones and royalties diversify funding sources and lower dependence on any single program.
Geography
BioLineRx is headquartered in Modi’in, Israel, and maintains an Israeli operating base with U.S. corporate and commercialization activities. The company’s ADSs trade on Nasdaq Capital Market and its ordinary shares trade on the Tel Aviv Stock Exchange, reflecting a dual-capital-market structure. Commercial activity for motixafortide has included the U.S. and partner-led international markets, while clinical development extends across the U.S., Israel, and Europe through collaborations.
Risks
BioLineRx depends on clinical development success, regulatory execution, and partner commercialization for much of its value creation. Its exposure is concentrated in a small number of oncology assets, so trial setbacks, slower enrollment, or weaker-than-expected market uptake could have an outsized effect. Like other biotech companies, it also faces valuation and impairment risk on intangible assets, financing dependence, and geopolitical or cross-border operating frictions.
- Financing and dilution riskImpact: HighLikelihood: High
Development-stage biotech often requires external capital before programs generate durable cash flow.
Exposure - Clinical development setbacksImpact: HighLikelihood: Medium
Pipeline value depends on proof of safety and efficacy in oncology trials.
Exposure - Partner commercialization riskImpact: HighLikelihood: Medium
Ex-U.S. and some product-market activities rely on third-party execution and market access.
Exposure - Intangible asset impairmentImpact: HighLikelihood: Medium
Clinical-stage assets and acquired/indefinite-lived intangibles can be written down if prospects weaken.
Exposure: Development programs and IP assets
- Geopolitical and operating disruptionImpact: MediumLikelihood: Medium
Israel-based operations and global clinical activity can be affected by regional tensions and volatility.
Exposure
Accounting
Judgemental itemsLiability-classified warrants are remeasured at each reporting date and depend on share price and model inputs.
Impact: Can create large non-cash swings in other income/expense
Management must assess whether clinical and commercial prospects still support carrying values.
Impact: Potential write-downs if program value declines
Partner agreements can produce irregular non-operating revenue based on contractual triggers.
Impact: Lumpy income recognition and comparability issues
A portion of expenses is NIS-denominated while reporting is in dollars, creating translation and hedge effects.
Impact: Can affect financial expense/income
Similar listed companies
Publicly listed companies with a comparable business focus.
Addex Therapeutics Ltd.
ADXN · Pharmaceutical Preparations
Biodexa Pharmaceuticals Plc
BDRX · Pharmaceutical Preparations
Biodexa Pharmaceuticals Plc is a clinical-stage biopharmaceutical company based in Cardiff, Wales, developing drug candidates for gastrointestinal cancers and…
Pyxis Oncology, Inc.
PYXS · Pharmaceutical Preparations
Amylyx Pharmaceuticals, Inc.
AMLX · Pharmaceutical Preparations
VolitionRX Limited
VNRX · In Vitro & In Vivo Diagnostic Substances
VolitionRx Ltd is a U.S.-based epigenetics diagnostics company developing blood-based tests that use nucleosomes and related biomarkers to detect and monitor disease.
Can-Fite BioPharma Ltd.
CANF · Pharmaceutical Preparations
Last updated: 28/09/2026